Expanded Access to Burosumab

Ultragenyx

Status

Conditions: X-linked Hypophosphatemia; Tumor-Induced Osteomalacia

Treatments: Biological: Burosumab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03775187

UX023-EAP

Details and patient eligibility

About

Individual patient expanded access requests may be considered for patients who have no other treatment options

Full description

Expanded access may be available outside of the US in countries prior to approval by the local regulatory agencies. For full details, please visit the links provided below.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria